cinqaero
teva b.v. - reslizumab - astma - druga sistemska zdravila za obstruktivne pljučne bolezni, - cinqaero je naveden kot dodatna terapija pri odraslih bolnikih s hudo astmo eozinofilno neustrezno nadzorovano kljub velikim odmerkom vdihavanju kortikosteroidi plus drugo zdravilo za vzdrževalno zdravljenje.
cinqaero 10 mg/ml koncentrat za raztopino za infundiranje
teva pharmaceuticals ltd. - reslizumab - koncentrat za raztopino za infundiranje - reslizumab 10 mg / 1 ml - reslizumab
cinqaero 10 mg/ml koncentrat za raztopino za infundiranje
teva pharmaceuticals ltd. - reslizumab - koncentrat za raztopino za infundiranje - reslizumab 10 mg / 1 ml - reslizumab
menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.